| 1. |
- Smith, A., et al.
(författare)
-
LunarEX-a proposal to cosmic vision
- 2009
-
Ingår i: Experimental Astronomy. - : Springer Science and Business Media LLC. - 0922-6435 .- 1572-9508. ; 23:3, s. 711-740
-
Tidskriftsartikel (refereegranskat)
|
|
| 2. |
- Carlsson, Ella, et al.
(författare)
-
Mass composition of the escaping plasma at Mars
- 2006
-
Ingår i: Icarus. - : Elsevier BV. - 0019-1035 .- 1090-2643. ; 182:2, s. 320-328
-
Tidskriftsartikel (refereegranskat)abstract
- Data from the Ion Mass Analyzer (IMA) sensor of the ASPERA-3 instrument suite on Mars Express have been analyzed to determine the mass composition of the escaping ion species at Mars. We have examined 77 different ion-beam events and we present the results in terms of flux ratios between the following ion species: CO2+/O+ and O-2(+)/O+. The following ratios averaged over all events and energies were identified: CO2+/O+ = 0.2 and O-2(+)/O+ = 0.9. The values measured are significantly higher, by a factor of 10 for O-2(+)/O+, than a contemporary modeled ratio for the maximum fluxes which the martian ionosphere can supply. The most abundant ion species was found to be O+, followed by O-2(+) and CO2+. We estimate the loss of CO2+ to be 4.0 x 10(24) s(-1) (0.29 kg s(-1)) by using the previous measurements of Phobos-2 in our calculations. The dependence of the ion ratios in relation to their energy ranges we studied, 0.3-3.0 keV, indicated that no clear correlation was found.
|
|
| 3. |
- Harrington, Robert A., et al.
(författare)
-
The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA.CER) trial : study design and rationale
- 2009
-
Ingår i: American Heart Journal. - : Elsevier BV. - 0002-8703 .- 1097-6744. ; 158:3, s. 327-334
-
Tidskriftsartikel (refereegranskat)abstract
- Background The protease-activated receptor 1 (PAR-1), the main platelet receptor for thrombin, represents a novel target for treatment of arterial thrombosis, and SCH 530348 is an orally active, selective, competitive PAR-1 antagonist. We designed TRA.CER to evaluate the efficacy and safety of SCH 530348 compared with placebo in addition to standard of care in patients with non-ST-segment elevation (NSTE) acute coronary syndromes (ACS) and high-risk features. Trial design TRA.CER is a prospective, randomized, double-blind, multicenter, phase III trial with an original estimated sample size of 10,000 subjects. Our primary objective is to demonstrate that SCH 530348 in addition to standard of care will reduce the incidence of the composite of cardiovascular death, myocardial infarction (MI), stroke, recurrent ischemia with rehospitalization, and urgent coronary revascularization compared with standard of care alone. Our key secondary objective is to determine whether SCH 530348 will reduce the composite of cardiovascular death, MI, or stroke compared with standard of care alone. Secondary objectives related to safety are the composite of moderate and severe GUSTO bleeding and clinically significant TIMI bleeding. The trial will continue until a predetermined minimum number of centrally adjudicated primary and key secondary end point events have occurred and all subjects have participated in the study for at least I year. The TRA.CER trial is part of the large phase III SCH 530348 development program that includes a concomitant evaluation in secondary prevention. Conclusion TRA.CER will define efficacy and safety of the novel platelet PAR-1 inhibitor SCH 530348 in the treatment of high-risk patients with NSTE ACS in the setting of current treatment strategies.
|
|
| 4. |
|
|
| 5. |
- Dahl, P., et al.
(författare)
-
Densification and properties of zirconia prepared by three different sintering techniques
- 2007
-
Ingår i: Ceramics International. - : Elsevier BV. - 0272-8842 .- 1873-3956. ; 33:8, s. 1603-1610
-
Tidskriftsartikel (refereegranskat)abstract
- Densification of nanocrystalline yttria stabilized zirconia (YSZ) powder with 8 mol% Y2O3, prepared by a glycine/nitrate smoldering combustion method, was investigated by spark plasma sintering, hot pressing and conventional sintering. The spark plasma sintering technique was shown to be superior to the other methods giving dense materials (>= 96%) with uniform morphology at lower temperatures and shorter sintering time. The grain size of the materials was 0.21, 0.37 and 12 mu m after spark plasma sintering, hot pressing and conventional sintering, respectively. Total electrical conductivity of the materials showed no clear correlation with the grain size, but the activation energy for spark plasma sintered materials was slightly higher than for materials prepared by the two other densification methods. The hardness, measured by the Vickers indentation method, was found to be independent on grain size while fracture toughness, derived by the indentation method, was slightly decreasing with increasing grain size.
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
- Nygren, Mats, et al.
(författare)
-
Spark plasma sintering of Zr- and Hf-borides with decreasing amounts of MoSi2 as sintering aid.
- 2008
-
Ingår i: Journal of European Ceramic Society. ; 28:1287-1296
-
Tidskriftsartikel (refereegranskat)abstract
- ZrB2- and HfB2-based composites contg. 1, 3, and 9 vol.% MoSi2 as sintering aid were densified by spark plasma sintering at temps. ranging from 1700 to 1950, with an applied pressure of 100 MPa. As-received ZrB2 and HfB2 powders were also sintered at temps. in the range of 2100-2200. Fully dense samples were obtained between 1750 and 1850 when MoSi2 was added. As-received ZrB2 powder was sintered to 98% at 2100. The microstructural features were investigated by SEM-EDS technique. SciC was detected in all the doped compns. along with significant amts. of oxide species (Hf/ZrO2 and SiO2). Vickers hardness and fracture toughness were measured by indentation technique on polished sections. The effect of the MoSi2 content on densification, microstructure, and mech. properties is discussed.
|
|
